At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Adjuvant Thalidomide Following Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis or Adenomucinosis From Colorectal/Appendiceal Cancer
In Brief
A Phase 2 clinical trial evaluating thalidomide and surgery for Carcinoma of the Appendix and Colorectal Cancer. Completed, enrolled 29 participants across 1 site.
Detailed Summary
RATIONALE: Thalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Giving thalidomide after surgery and chemotherapy may kill any remaining tumor cells. PURPOSE: This phase II trial is studying how well thalidomide works in treating patients who have undergone surgery and received chemotherapy directly into the abdomen by hyperthermic perfusion for cancer that has spread throughout the abdomen due to colorectal cancer or appendix cancer .
Study Details
Timeline
Interventions
Patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.
Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy